Last reviewed · How we verify
D013(placebo)
D013 is a placebo control with no active pharmacological mechanism.
At a glance
| Generic name | D013(placebo) |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, D013 contains no active pharmaceutical ingredient and produces no direct molecular or biological effect. It is used as a control comparator in clinical trials to assess the efficacy and safety of active investigational drugs by comparison to inert treatment.
Approved indications
Common side effects
Key clinical trials
- Clinical Trial to Evaluate the Efficacy and Safety of CKD-386 (PHASE3)
- Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D013(placebo) CI brief — competitive landscape report
- D013(placebo) updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI